Niba Labs is pioneering the development of multiplex dPCR assays and has been sharing and promoting the results of the innovative
NibaPlex® analysis tool to the AAV community for the past several years.
We are excited about the results on the use of multiplex dPCR for the evaluation of vector genome integrity in a recent publication by
Eisenhut et al.
The authors have shown an excellent correlation between the quantity of complete genomes (by multiplex dPCR) and biopotency results. Furthermore, they explained the differences in the biopotency results of two samples, in which different transfection protocols were used.
In addition, the commonly used simplex dPCR vector genome titer (targeting only a small region of the genome) did not explain the differences in biopotency between the samples tested.
These results highlight the importance of multiplex dPCR assays for the assessment of vector genome integrity and characterization of the AAV vector genome.
Our portfolio of
NibaPlex® assays is designed for both the quantification of complete vector genomes and the distribution of incomplete populations.
The
NibaPlex® results, especially the quantity of complete genomes as suggested in the mentioned publication, can be used as a direct indication of biopotency and could provide much better guidance in process development and optimization than the ratio of empty to full capsids or the classical simplex vector genome titer.
For more information on how
NibaPlex® can help you achieve better yields of potent AAV vectors, please contact us by clicking the “Request Free Sample” button.